Publications by authors named "Yousef Samih"
Article Synopsis
- The CAPItello-291 study examined the effectiveness of the drug combination capivasertib and fulvestrant in treating advanced HR-positive, HER2-negative breast cancer in patients whose cancer progressed after previous treatments.
- Results indicated that patients receiving the capivasertib plus fulvestrant treatment experienced longer progression-free survival (7.2 months) compared to those receiving placebo plus fulvestrant (3.6 months).
- Common side effects included diarrhea and rashes, but the study is still ongoing, and more results are anticipated in the future.
Article Synopsis
- CAPItello-291 is a phase 3 clinical trial studying the effects of capivasertib combined with fulvestrant on progression-free survival in patients with advanced hormone receptor-positive, HER2-negative breast cancer who experienced relapse after aromatase inhibitors.
- The trial involved a diverse group of participants, including both men and women aged 18 and older, and was conducted across 193 centers in 19 countries, focusing on those with a specific type of breast cancer and previous treatment history.
- Researchers also assessed the impact of this treatment on quality of life, symptoms, and tolerability, aiming to analyze how the new combination therapy affects overall health and wellbeing beyond just cancer progression.
Article Synopsis
- The study investigates the efficacy and safety of the AKT inhibitor capivasertib when combined with fulvestrant therapy for patients with hormone receptor-positive advanced breast cancer.
- In a phase 3 trial, patients who had previously experienced disease progression while on aromatase inhibitors were randomly assigned to receive either capivasertib with fulvestrant or a placebo with fulvestrant.
- Results showed that the combination therapy significantly improved progression-free survival: 7.2 months for the capivasertib group compared to 3.6 months for placebo, with higher rates of adverse events, such as rash and diarrhea, in the capivasertib group.
Lung cancer is a worldwide prevalent malignancy. This disease has a low survival rate due to diagnosis at a late stage challenged by the involvement of metastatic sites. Non-small-cell lung cancer (NSCLC) is presented in 85% of cases.
View Article and Find Full Text PDF